危急病患者的达帕格利弗洛辛:DEFENDER研究的理由和设计
Caio de Assis Moura Tavares1, Luciano César Pontes de Azevedo1, Álvaro Rea-Neto2
1Hospital Israelita Albert Einstein - São Paulo (SP), Brazil.
Critical care science
|December 22, 2023
概括
在DEFENDER试验中,研究了针对急性器官功能障碍的危急病患者的达帕格利弗洛辛. 这项研究将评估-葡萄糖共传输体-2 抑制剂是否能改善重症监护室的治疗结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 危急疾病是一个重大的全球健康挑战,死亡率高.
- -葡萄糖共传输体-2 抑制剂已经证明了心血管和的益处.
- 有限的研究存在于SGLT2抑制剂在急性疾病期间的影响.
研究的目的:
- 评估大帕格利弗洛辛在重症患者中的疗效和安全性.
- 研究SGLT2抑制剂在ICU内急性器官功能障碍中的作用.
主要方法:
- DEFENDER试验是一个随机的,开放的标签研究,涉及500名成年ICU患者.
- 参与者要么接受达帕格利弗洛辛 (10mg) 加标准护理,要么仅接受标准护理,长达14天.
- 主要结局是医院死亡率,需要脏替代疗法和28天内的ICU停留时间的复合.
主要成果:
- 该部分尚未提供,因为研究仍在进行中.
结论:
- DEFENDER是同类的第一个试验,检查SGLT2抑制剂在一般ICU急性器官功能障碍患者.
- 该研究预计将产生关键数据,说明这种药物类别在重症监护中的有用性.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
189
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
189
01:15Diabetes: Symptoms, Diagnosis, and Complications
553
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
553